Scientific Advisory Board

Richard E. Champlin, M.D.

MD Anderson Cancer Center, Houston, TX

Dr. Champlin is in his twenty-fifth year at MD Anderson Cancer Center in Houston, Texas. He holds the titles of Chair, Department of Stem Cell Transplantation and Cellular Therapy; Professor of Medicine; and Associate Division Head, Division of Cancer Medicine. As an international leader in the field of hematopoietic stem cell transplantation (HSCT), Dr. Champlin pioneered the use of donor transplants and lower doses of chemotherapy, reducing mortality rates along the way. Under his leadership, the MD Anderson HSCT program grew to become the largest in the world.

Dr. Champlin is board-certified in Internal Medicine, Medical Oncology and Hematology and received his MD (Alpha Omega Alpha) from the University of Chicago Pritzker School of Medicine prior to Residency and Fellowship at the University of California, LosAngeles. Additionally, Dr. Champlin has published approximately 700 original scientific and clinical research articles. He has Chaired or been a member of a multitude of professional organizations and committees, including Founding President of the American Society for Blood and Marrow Transplantation, Past Chair of the Center for International Blood and Marrow Transplantation Research, and is currently on the US Health Resources and Services Administration Advisory Council on Blood Stem Cell Transplantation. Awards include the John Mendelsohn Lifetime Scientific Achievement Award of MD Anderson Cancer Center, Division of Cancer Medicine and the Lifetime Achievement Award of the American Society for Blood and Marrow Transplantation.

Sergio Giralt, M.D.

Memorial Sloan Kettering Cancer Center, New York, NY

Dr. Giralt is Chief, Adult Bone Marrow Transplant Service; Acting Chief, Myeloma Service, and a board-certified hematologist/oncologist whose clinical practice and research focus on stem cell transplantation for patients with blood disorders. Dr. Giralt and his colleagues pioneered the use of reduced-intensity conditioning regimens for older or more debilitated patients with blood cancers, and are currently using and studying T cell depletion techniques to dramatically reduce the risk of graft-versus-host disease, a serious complication of donor stem cell transplantation.

Most recently, Dr. Giralt was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies at the University of Texas MD Anderson Cancer Center. He is also the past chair of the steering committee of the Blood and Marrow Transplant Clinical Trials Network, a federally funded group that defines the research agenda for stem cell transplantation in the United States.

Hillard M. Lazarus, M.D.

University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH

Dr. Lazarus is a Professor of Medicine, Director of Novel Cell Therapy, Disease Team Leader of Cellular Therapy Integrated Services, and is board-certified in Internal Medicine, Medical Oncology and Hematology. He received his MD from the University of Rochester School of Medicine prior to Residency at the Case Western Reserve University/University Hospitals Case Medical Center. Additional Fellowships include those sponsored by the Leukemia Society of America and the American Cancer Society.

In 1980, Dr. Lazarus performed the first bone marrow transplant in the State of Ohio. He now heads several clinical trials at Case Western, at the National Center for Regenerative Medicine. His seminal impact in multiple aspects of transplantation was recognized in 1986 by his invitation to develop and chair the Blood and Marrow Transplant Committee of the National Cancer Institute, a position he held until 2003. Dr. Lazarus has over 400 publications including over 300 peer-reviewed articles, 50 book chapters and 70 review articles, and is Editor of Blood Reviews and Bone Marrow Transplantation. He has won a variety of lifetime achievement, distinguished alumnus and cancer research awards as well.

Peter A. McSweeney, M.D.

The Colorado Blood Cancer Institute at Presbyterian/St. Luke’s, Rocky Mountain Blood and Marrow Transplant Program, University of Colorado, Denver, CO

Dr. McSweeney is Clinical Associate Professor of Medicine and is board-certified in Internal Medicine, Hematology and Hematopathology. He earned his MD at the University of Otago Medical School in Dunedin, New Zealand. He completed his Residency and Fellowships at Wellington Public Hospital in New Zealand. In the US, he completed fellowships in clinical hematology, hematopathology and oncology at Fred Hutchinson Cancer Research Center (FHCRC), and then worked in clinical research at FHCRC and became an Assistant Professor at the University of Washington School of Medicine.

Dr. McSweeney was the clinical director and laboratory medical director at the University of Colorado’s Blood and Marrow Transplant Program. He has been published numerous times and won many awards for his work in blood and marrow transplantation.

John M. Pagel, M.D., Ph.D. (Chair)

Chief, Hematologic Malignancies Program, Swedish Cancer Institute, Seattle, WA

Dr. Pagel is an Associate Professor of Medical Oncology and Associate Member in the Clinical Research Division of FHCRC. He received a PhD in microbiology and molecular genetics from the University of California, Irvine and his MD (magna cum laude) from Boston University School of Medicine. After a Post-doctoral as a Howard Hughes Research associate at the University of California, San Francisco he went on to complete his residency in Internal Medicine at the University of California San Francisco and fellowship in Oncology at the University of Washington.  Dr. Pagel also serves as Chief of the Hematologic Malignancies Program at the Swedish Cancer Institute.

Dr. Pagel specializes in bone marrow transplant, leukemia and lymphoma and has received numerous awards, including the ASCO Young Investigator Award, Lymphoma Research Foundation Career Development Award, ASCO Career Development Award, University of California President’s Award, and a Howard Hughes Post-Doctoral Research Award. Throughout his career, Dr. Pagel has published many abstracts and articles in a variety of publications, including Blood, Bone Marrow Transplantation, and the Proceedings of the National Academy of Sciences. He leads a number of studies of radioimmunotherapy as the principal investigator of leukemia clinical trials. Dr. Pagel has been instrumental in the historical development of the anti-CD45 antibody, which when radiolabeled with iodine-131 becomes Iomab™-B.

M. Yair Levy, M.D.

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

Dr. Levy is Medical Director, Hematologic Malignancy Clinical Research of the Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas, Texas. He was previously on the Faculty at Sidney Kimmel Comprehensive Care Center at Johns Hopkins, after completing a Hematology Fellowship there. Dr. Levy is Board Certified in Medical Oncology and Internal Medicine. He is also a Clinical Assistant Professor of Internal Medicine at the Texas A&M College of Medicine.